Document is current

Article History

Received: 22 January 2026

Accepted: 2 July 2026

First Online: 8 July 2026

Declarations

:

: This study was approved by the Institutional Review Board of Hospital Clínico Universitario San Carlos (IRB code: 25/658-E) and adhered to the principles of the Declaration of Helsinki. The investigators obtained an informed consent from the patient to participate before conducting this study.

: The investigators obtained an informed consent from the patient to publish information and clinical images before conducting this study.

: Santiago Cabezas-Camarero: Consultant for: GSK, Merck. Speaker’s Bureau for: Bristol-Myers Squibb, Merck, Novocure, MSD. Employee of: None. Grant/Research support from clinical trials: AstraZeneca, MSD, Merck. Travel and Academic work Fees from: Merck, MSD, Johnson & Johnson Innovative Medicine, Novocure. Rebeca Pérez-Alfayate: Travel expenses: Prim. Pedro Pérez-Segura: Consultant for: Merck, MSD. Speaker’s Bureau for: Bristol-Myers Squibb, Merck, MSD, Novocure. Employee of: None. Grant/Research support from (Clinical Trials): Bristol-Myers Squibb, AstraZeneca, MSD. Travel and Academic work Fees from: Merck, MSD and Bristol-Myers Squibb.The rest of the authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.